Skip to main content
Boehringer Ingelheim acquires ViraTherapeutics
9/14/2018

ViraTherapeutics, an oncolytic virus biotech, was acquired by Boehringer Ingelheim in a bid to expand its presence in the field of immuno-oncology. Boehringer will use ViraTherapeutics' oncolytic virus therapies combined with cancer drugs in its development pipeline.

Full Story: